A dramatic turn of events has unfolded in the pharmaceutical industry, with Novo Nordisk A/S finding itself at the center of a high-stakes rivalry. The Danish drugmaker's shareholder meeting revealed a deep-rooted conflict with its US competitor, Pfizer Inc.
The Battle for Boardroom Control
Lars Rebien Sorensen, the executive behind Novo's groundbreaking weight-loss treatment, found himself explaining the sudden withdrawal of proposed board member Mikael Dolsten. Dolsten, a former chief scientific officer at Pfizer, had to step down due to an issue with a previous employer. While Sorensen didn't name the company, the timing is intriguing, given Pfizer's recent victory over Novo in a $10 billion bidding war for obesity biotech Metsera Inc.
Sorensen expressed his disappointment, hoping Dolsten would return, but the incident highlights the intense competition between these pharmaceutical giants.
A Tumultuous Few Weeks
The meeting on Friday capped off a chaotic period for Novo. A dispute over the direction of the company led to more than half of the supervisory board resigning last month. Sorensen, who previously ran Novo for 16 years and also heads the controlling shareholder, the Novo Nordisk Foundation, was approved to lead the board with an overwhelming majority of votes.
However, Dolsten's withdrawal leaves a gap on the board, which now needs to nominate additional candidates. This development has left minority investors, including Norway's sovereign wealth fund and CalSTRS, concerned about the lack of transparency and accountability.
A Risky Strategy?
Minority investors now face a crucial decision: should they support Sorensen's bold move to overhaul the board and place their faith in his ambitious new CEO, Mike Doustdar? The Sorensen-Doustdar duo has already demonstrated a willingness to take risks, as seen in their aggressive attempt to outbid Pfizer for Metsera. This high-stakes strategy even involved a showdown at the Oval Office, where Doustdar challenged Pfizer's CEO.
While Sorensen believes they have a "warrior" as CEO, some investors may question this approach. Markus Manns, a portfolio manager, suggests Novo needs to evaluate deals more carefully and reduce risk, especially after their unsuccessful pursuit of Metsera. He emphasizes the need for a sustainable strategy to regain market share and diversify.
A New Era for Novo?
Novo faces a challenging road ahead in the obesity market, having lost ground to rivals like Eli Lilly & Co. While competitors are developing novel compounds, Novo's next offerings are merely reworked versions of existing drugs. Sorensen's return to the helm, almost a decade after leaving the CEO role, offers him a second chance to reshape the company.
During his previous tenure, Sorensen oversaw significant sales growth and the introduction of Saxenda, a precursor to Wegovy. However, Novo faced challenges with insulin prices towards the end of his term. His successor brought success with Ozempic and Wegovy, but the company failed to maintain its lead.
The recent board restructuring, a departure from Novo's consensual culture, has left some questioning the direction of the company. Sebastien Malafosse, a portfolio manager, believes Sorensen's return could be a positive step, given his previous success.
Since Doustdar and Sorensen took charge, Novo has announced significant changes, including layoffs, the cancellation of long-standing projects, and the bidding war with Pfizer. Hanne Sindbaek, a Danish author, describes this as a shift in strategy, recognizing the need for a more aggressive approach in a competitive market.
The story of Novo's transformation is far from over, and the outcome of this intense rivalry will have significant implications for the pharmaceutical industry. As the battle for market dominance continues, the decisions made by Novo's leadership will be closely watched by investors and industry experts alike.
